Ultralife GAAP EPS of $0.14, revenue of $48.3M

Ultralife (ULBI) reported Q3 GAAP EPS of $0.14, with revenue of $48.3M, up 11.3% year-over-year. Adjusted EBITDA was $5.6M, and backlog increased to $136.0M from $117.5M in Q2 2026, according to the company.

Original reporting
Published Nov 6, 2026, 5:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ULBI
Neutral
medium confidence
Mentioned
$ULBI
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ULBINeutralMed
01

Why it matters

The earnings release provides the first quantitative update for the quarter, offering traders a basis for short‑term positioning.

02

Market read

While the absolute numbers are small, the fresh earnings data creates a trading opportunity for the stock.

03

What to watch

Potential supply‑chain constraints or upcoming regulatory approvals could affect future performance.

Relevance 6/10Novelty 6/10Timing: post‑market today

Background

Ultralife (NASDAQ: ULBI) is a micro‑cap medical‑device company that released its third‑quarter 2026 financial results.

Company-level read

Ticker impact

$ULBINeutralMedium confidence
Context

Ultralife reported Q3 GAAP EPS of $0.14, revenue of $48.3M and adjusted EBITDA of $5.6M, marking its first public earnings disclosure for the quarter.

Expected impact

possible modest upside as investors price in improved profitability, but limited by micro‑cap liquidity.

Evidence & confidence

New earnings data provides fresh valuation input; however, the company’s small size and limited analyst coverage constrain the magnitude of the move.

Market effects

Ultralife operates in the medical‑device/health‑tech niche; its earnings may signal demand trends for similar micro‑cap innovators.

Primarily U.S. investors; limited broader regional effect.

Low global impact due to company size.

Counterpoint

Despite earnings growth, the stock may face pressure if revenue guidance is not raised, given its modest scale.

Key entities

  • Ultralife Corp.

    Medical‑device manufacturer reporting Q3 2026 results.

Related articles

$ULBIHighAI 8/10

Ultralife Corporation Reports Third Quarter Results

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y. – November 5, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2026 with the following results: ● Sales of $48.3 million compared to $43.

$ENSHighAI 9/10

EnerSys to Buy Ultralife for $320 Million in Defense Expansion

EnerSys (ENS) will acquire Ultralife (ULBI) for $320M, paying $16/share, a 166% premium. The deal, expected to close Q1 2027, aims to expand EnerSys' defense battery business, adding manufacturing capacity and technologies. Ultralife generated $191M revenue in 2025. EnerSys expects $15-20M in annual cost savings and EPS growth post-acquisition.

$ULBIHighAI 8/10

Orders waiting to be filled at Ultralife hit $136 million, its highest level ever.

Ultralife Corporation (ULBI) reported Q3 2026 revenue of $48.3M, up from $43.4M in Q3 2025. Gross profit rose to $13.3M (27.5% of revenue) from $9.6M (22.2%). Operating income was $3.2M, reversing a $1.0M loss in the prior year. GAAP EPS was $0.14, compared to ($0.07). Adjusted EBITDA reached $5.6M, up from $2.0M. Backlog hit $136.0M, the highest ever. Ultralife also announced an agreement to be acquired by EnerSys (ENS) in an all-cash transaction.